

Table 1.23  
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites<sup>a</sup> by Race/Ethnicity  
Both Sexes

	All Races		White		Black		
	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017	
All Sites	442.4	-1.1*	452.1	-1.1*	440.4	-1.6*	
Breast	68.9	0.0	69.5	-0.2	Prostate <sup>f</sup>	74.4	-4.2*
Lung and Bronchus	54.2	-2.2*	56.0	-2.2*	Breast	71.3	0.2
Prostate <sup>f</sup>	50.2	-4.3*	47.3	-4.8*	Lung and Bronchus	54.8	-2.7*
Colon and Rectum	38.2	-2.3*	37.8	-2.2*	Colon and Rectum	43.6	-3.0*
Melanoma of the Skin	22.7	1.2*	27.2	1.3*	Kidney and Renal Pelvis	17.5	0.1
Urinary Bladder	20.0	-1.4*	22.0	-1.4*	Corpus and Uterus, NOS <sup>f</sup>	15.9	1.5*
Non-Hodgkin Lymphoma	19.6	-0.8*	20.6	-0.8*	Pancreas	15.3	0.1
Kidney and Renal Pelvis	16.3	0.4*	16.8	0.5*	Non-Hodgkin Lymphoma	14.7	-0.5*
Thyroid	15.7	1.0	16.4	0.7	Myeloma	13.8	0.3
Corpus and Uterus, NOS <sup>f</sup>	14.8	0.9*	15.0	-0.4	Urinary Bladder	11.8	-0.8*
Leukemia	14.1	-0.3	14.9	0.6*	Leukemia	10.8	0.3
Pancreas	13.1	0.5*	13.1	0.5*	Liver & IBD <sup>g</sup>	10.7	0.7
Oral Cavity and Pharynx	11.4	0.5*	12.0	0.6*	Stomach	10.1	-2.1*
Liver & IBD <sup>g</sup>	9.0	1.4*	8.1	1.9*	Thyroid	9.5	1.3
Stomach	7.3	-0.8*	7.1	-0.7*	Oral Cavity and Pharynx	8.5	-1.2*
	Asian/Pacific Islander		American Indian/Alaska Native <sup>d</sup>		Hispanic <sup>e</sup>		
	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017	
All Sites	302.1	-0.8*	310.1	-1.0*	All Sites	348.4	-1.1*
Breast	56.3	1.2*	42.7	-0.5	Breast	53.2	0.4
Lung and Bronchus	36.2	-1.1*	39.0	-1.1	Prostate <sup>f</sup>	40.7	-5.5*
Colon and Rectum	31.8	-2.5*	38.1	-1.8*	Colon and Rectum	33.7	-1.8*
Prostate <sup>f</sup>	25.1	-4.9*	24.3	-5.4*	Lung and Bronchus	29.0	-2.2*
Thyroid	15.8	1.2*	17.9	-0.3	Non-Hodgkin Lymphoma	18.1	-0.4*
Non-Hodgkin Lymphoma	13.5	-0.5	14.9	1.2	Kidney and Renal Pelvis	16.1	1.0*
Liver & IBD <sup>g</sup>	12.9	-2.2*	10.9	-3.3*	Thyroid	14.2	2.3*
Corpus and Uterus, NOS <sup>f</sup>	11.8	1.9*	10.6	-0.8	Liver & IBD <sup>g</sup>	13.7	0.6
Stomach	10.6	-2.6*	10.0	1.1	Corpus and Uterus, NOS <sup>f</sup>	13.1	2.1*
Pancreas	10.0	0.3	9.6	1.6	Pancreas	11.6	0.1
Urinary Bladder	8.9	-0.9*	9.3	2.3*	Urinary Bladder	11.0	-1.5*
Kidney and Renal Pelvis	8.8	0.8	8.4	-1.3	Leukemia	10.9	-0.6
Oral Cavity and Pharynx	8.5	0.4	8.1	-0.4	Stomach	10.5	-1.2*
Leukemia	8.0	-0.4	8.1	-0.8	Oral Cavity and Pharynx	6.8	-1.2*
Ovary <sup>fh</sup>	5.1	-1.0	5.7	2.9	Myeloma	6.8	0.2

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

<sup>a</sup> Top 15 cancer sites selected based on 2013-2017 age-adjusted rates for the race/ethnic group.

<sup>b</sup> Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>c</sup> The APC is the Annual Percent Change over the time interval.

<sup>d</sup> Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>e</sup> Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

<sup>f</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>g</sup> Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>h</sup> The rates for sex-specific cancer sites are calculated using the population for both sexes combined.

<sup>i</sup> IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

<sup>j</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.24  
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites<sup>a</sup> by Race/Ethnicity

			Males					
All Races			White			Black		
	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017		Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017		Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017
All Sites	480.3	-1.9*	All Sites	485.5	-1.9*	All Sites	515.1	-2.7*
Prostate	109.8	-4.5*	Prostate	102.3	-5.0*	Prostate	175.2	-4.5*
Lung and Bronchus	61.7	-2.9*	Lung and Bronchus	62.2	-2.9*	Lung and Bronchus	71.2	-3.5*
Colon and Rectum	43.7	-2.4*	Colon and Rectum	43.0	-2.4*	Colon and Rectum	51.3	-3.0*
Urinary Bladder	34.9	-1.6*	Urinary Bladder	38.2	-1.6*	Kidney and Renal Pelvis	24.5	0.1
Melanoma of the Skin	29.3	1.1*	Melanoma of the Skin	34.6	1.2*	Urinary Bladder	19.7	-1.1*
Non-Hodgkin Lymphoma	23.8	-0.8*	Non-Hodgkin Lymphoma	25.0	-0.8*	Liver & IBD <sup>f</sup>	17.7	0.7
Kidney and Renal Pelvis	22.4	0.4	Kidney and Renal Pelvis	23.0	0.4	Non-Hodgkin Lymphoma	17.7	-1.0*
Leukemia	18.1	-0.4	Leukemia	19.2	-0.5	Pancreas	16.9	-0.1
Oral Cavity and Pharynx	17.2	0.6*	Oral Cavity and Pharynx	18.1	0.8*	Myeloma	16.5	0.2
Pancreas	14.9	0.5*	Pancreas	15.0	0.6*	Stomach	13.8	-2.3*
Liver & IBD <sup>f</sup>	13.8	1.1*	Liver & IBD <sup>f</sup>	12.4	1.5*	Leukemia	13.6	-0.1
Stomach	9.9	-1.3*	Stomach	8.9	-1.4*	Oral Cavity and Pharynx	13.3	-1.3*
Myeloma	8.8	0.6	Thyroid	8.6	1.4*	Larynx	7.3	-3.1*
Thyroid	8.1	1.5*	Brain and ONS <sup>f</sup>	8.3	-0.8*	Esophagus	6.1	-4.5*
Brain and ONS <sup>f</sup>	7.5	-0.8*	Myeloma	8.2	0.5	Brain and ONS <sup>f</sup>	4.5	-1.1
Asian/Pacific Islander			American Indian/Alaska Native <sup>d</sup>			Hispanic <sup>e</sup>		
	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017		Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017		Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017
All Sites	304.4	-1.9*	All Sites	321.0	-1.6*	All Sites	370.4	-2.5*
Prostate	56.7	-5.0*	Prostate	54.6	-5.4*	Prostate	92.0	-5.8*
Lung and Bronchus	46.2	-1.9*	Lung and Bronchus	43.5	-2.6*	Colon and Rectum	39.6	-2.5*
Colon and Rectum	37.9	-2.2*	Colon and Rectum	40.4	-2.4*	Lung and Bronchus	35.1	-3.2*
Liver & IBD <sup>f</sup>	19.9	-2.1*	Kidney and Renal Pelvis	22.9	-0.8	Kidney and Renal Pelvis	21.4	0.8
Non-Hodgkin Lymphoma	16.5	-0.5	Liver & IBD <sup>f</sup>	21.6	1.4	Non-Hodgkin Lymphoma	20.9	-0.6
Urinary Bladder	15.7	-0.9*	Urinary Bladder	16.3	0.5	Liver & IBD <sup>f</sup>	20.3	0.1
Stomach	14.1	-2.5*	Pancreas	12.9	2.8	Urinary Bladder	19.3	-1.6*
Kidney and Renal Pelvis	12.5	0.6	Oral Cavity and Pharynx	11.7	-0.3	Leukemia	13.2	-0.7
Oral Cavity and Pharynx	12.1	0.1	Stomach	11.1	-1.8	Stomach	13.1	-2.2*
Pancreas	11.0	0.3	Non-Hodgkin Lymphoma	10.8	-5.2*	Pancreas	12.5	0.0
Leukemia	9.9	-0.3	Leukemia	10.7	1.2	Oral Cavity and Pharynx	10.0	-1.4
Thyroid	7.9	2.8*	Myeloma	6.7	-	Myeloma	8.2	-0.1
Myeloma	5.0	0.1	Esophagus	6.2	-	Thyroid	5.9	3.0*
Brain and ONS <sup>f</sup>	4.5	0.0	Melanoma of the Skin	5.9	-	Brain and ONS <sup>f</sup>	5.9	-0.7
Esophagus	3.7	-0.4	Testis	5.2	1.3	Testis	5.4	2.0*

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

<sup>a</sup> Top 15 cancer sites selected based on 2013-2017 age-adjusted rates for the race/ethnic group.

<sup>b</sup> Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>c</sup> The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>d</sup> Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

<sup>e</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>f</sup> IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.25  
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites<sup>a</sup> by Race/Ethnicity

## Females

	All Races		White		Black	
	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017
All Sites	418.3	-0.3*	432.0	-0.4*	390.7	-0.4*
Breast	128.5	0.2	131.3	0.0	124.8	0.3
Lung and Bronchus	48.6	-1.5*	51.5	-1.5*	43.8	-2.0*
Colon and Rectum	33.6	-2.2*	33.3	-2.0*	38.2	-3.0*
Corpus and Uterus, NOS	27.8	1.0*	28.3	0.7*	27.9	1.7*
Thyroid	23.1	0.8	24.3	0.6	14.3	1.5
Melanoma of the Skin	17.8	1.3*	21.7	1.4*	14.1	0.3
Non-Hodgkin Lymphoma	16.2	-0.8*	17.0	-0.9*	12.5	0.0
Pancreas	11.6	0.4*	11.7	-2.4*	12.2	-0.2
Ovary <sup>g</sup>	11.2	-2.1*	11.6	-0.4	12.0	0.3
Kidney and Renal Pelvis	11.1	0.3	11.6	0.4	9.1	-1.4*
Leukemia	11.0	-0.3	11.4	0.4	8.9	0.7
Urinary Bladder	8.6	-1.5*	9.4	-1.5*	8.7	-2.4*
Cervix Uteri	7.4	-0.7	7.2	-0.7	7.6	-2.1*
Oral Cavity and Pharynx	6.4	0.1	6.6	0.2	6.5	-0.4
Myeloma	5.7	0.6*	6.0	-0.6	5.4	0.8
	Asian/Pacific Islander		American Indian/Alaska Native <sup>d</sup>		Hispanic <sup>e</sup>	
	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017	Rate <sup>b</sup> 2013-2017	APC <sup>c</sup> 2008-2017
All Sites	304.7	0.0	305.9	-0.4	339.5	0.2
Breast	102.9	1.2*	79.5	-0.5	99.1	0.6*
Lung and Bronchus	28.6	-0.2	37.9	0.0	29.2	-1.1*
Colon and Rectum	26.8	-3.0*	34.3	-1.0	24.8	-1.2*
Thyroid	22.7	0.8	19.9	-0.8	24.6	2.4*
Corpus and Uterus, NOS	21.7	1.9*	14.5	2.6*	22.3	2.3*
Non-Hodgkin Lymphoma	11.1	-0.6	13.7	-0.1	15.9	-0.2
Ovary <sup>g</sup>	9.5	-1.0	10.9	-1.2	11.7	1.1*
Pancreas	9.2	0.2	9.0	0.7	10.8	0.2
Stomach	8.0	-2.9*	8.4	-3.2	10.4	-0.9*
Liver & IBD <sup>f</sup>	7.2	-2.5*	7.9	0.4	9.2	-1.9*
Leukemia	6.5	-0.8	7.8	-0.6	9.1	-0.6
Cervix Uteri	6.5	-0.5	6.2	-1.1	8.6	-0.2
Kidney and Renal Pelvis	5.8	1.0	6.0	-3.4	8.1	1.6*
Oral Cavity and Pharynx	5.5	1.0	5.0	-0.2	5.7	0.3
Urinary Bladder	3.8	-1.6*	5.0	-	5.0	-1.9*

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

<sup>a</sup> Top 15 cancer sites selected based on 2013-2017 age-adjusted rates for the race/ethnic group.

<sup>b</sup> Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>c</sup> The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>d</sup> Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

<sup>e</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>f</sup> IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.


<sup>g</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

\* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Figure 1.13

# SEER Incidence 2008-2017 Males by Race/Ethnicity



Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG), Idaho, New York and Massachusetts.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 4.8, April 2020, National Cancer Institute.


<sup>a</sup> Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Figure 1.14

# SEER Incidence 2008-2017 Females by Race/Ethnicity



Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG), Idaho, New York and Massachusetts.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 4.8, April 2020, National Cancer Institute.

<sup>a</sup> Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.